Ulcerative Colitis Medication
Digestive HealthUlcerative Colitis
Explore This Topic

A Comprehensive Guide to Ulcerative Colitis Medications

A Comprehensive Guide to Ulcerative Colitis Medications
Canva; Everyday Health
By
Updated on July 31, 2024
by

Medication is considered the foundation treatment for ulcerative colitis (UC).

Your doctor will recommend one or more drugs, depending on your overall health, how severe the disease is, and other factors.

At first, the goal of treatment with medication will be to reduce the severity and frequency of your symptoms.

Medications may be given at first to quickly achieve this. But during this time, your gastroenterologist will be starting or planning to start you on subsequent medications to safely keep you in remission.

The following main classes of drugs are used to treat ulcerative colitis.

1. Aminosalicylates

This group of medications contains a chemical compound called 5-aminosalicylate acid. It includes the following drugs:

  • mesalamine (Lialda, Apriso, Canasa, Pentasa, Asacol HD, Delzicol, Rowasa)
  • sulfasalazine (Azulfidine)
  • olsalazine (Dipentum)
  • balsalazide (Colazal)

Mesalamine is typically one of the first drugs prescribed for mild to moderate ulcerative colitis.

Mesalamine is used both to treat active symptoms of ulcerative colitis and as a maintenance drug to prevent symptoms from recurring.


Mesalamine and other aminosalicylates may be taken orally as a tablet or capsule, or rectally, as a suppository or in an enema. Depending on the formulation, it may be necessary to take three or four doses of the drug daily.

For ulcerative proctitis — when the disease is confined to your rectum — your doctor may prescribe the suppository formulation alone.

For ulcerative colitis that extends beyond your rectum, your doctor may prescribe a suppository or enema as well as an oral formulation.


Past research has suggested that as many as 80 percent of people with ulcerative colitis

 respond to oral aminosalicylates within four weeks. But that is only true for mild disease.


Common side effects of mesalamine include headache, nausea, fever, and rash. The same side effects are common in sulfasalazine, and can sometimes be worse than side effects with mesalamine. Another side effect of sulfasalazine is infertility in men, which usually resolves when the medication is stopped.

2. Corticosteroids

These medicines, also known simply as steroids, are typically used to treat flares of ulcerative colitis.

Steroids may be taken orally or rectally, and include the following drugs:

  • budesonide (Uceris)
  • prednisone
  • hydrocortisone (Cortef, Hemmorex-HC)
  • methylprednisolone (Medrol)
Budesonide is considered a first-line treatment for ulcerative colitis. It can be taken orally as a tablet or capsule, or rectally, as a foam or tablet or in an enema. Because of the way the body processes budesonide, the oral form causes fewer side effects than other corticosteroids, according to research.


Prednisone, hydrocortisone, and methylprednisolone work by suppressing the entire immune system, rather than targeting specific inflammatory pathways.

Because of their high risk of side effects, these three drugs are typically reserved for flares of moderate to severe ulcerative colitis. They also shouldn’t be taken for very long.

If you take corticosteroids orally or by injection, you may have significant side effects. Local steroids — which are applied just to the area that needs treatment — are generally the preferred option.

For severe flares of ulcerative colitis, hospitalization and high-dose intravenous (IV) corticosteroids are often required. Once remission is achieved, your dose of steroids will be tapered gradually and, ideally, eventually stopped. Although short courses of steroids can be stopped quickly, longer courses of steroids need to be gradually tapered off, because use of these medications cause the body to reduce its production of the natural steroid cortisol.

Steroids are ineffective and dangerous as maintenance therapy to keep ulcerative colitis in remission.

Once you start taking steroids, you and your doctor should start talking about other, safer medications that may help bring this disease under control.

Possible side effects of steroids include:


3. Immunomodulators

Also known as immunosuppressants, these drugs work by limiting inflammation at its source in the immune system.

They’re usually reserved for cases in which aminosalicylates or, possibly, biologics haven’t been effective enough. They may reduce or eliminate the need for corticosteroids.

Immunomodulators may take several months to start working. They include the following drugs:

  • cyclosporine (Gengraf, Neoral, SandIMMUNE)
  • azathioprine (Azasan, Imuran)
  • mercaptopurine (Purinethol, Purixan)
  • tacrolimus (Prograf) (typically only used as a rescue medication option)
Because immunomodulators modify the activity of the immune system, there is an increased risk of developing an infection.

Before you begin a course of treatment using an immunomodulator, it’s important to have a recent complete blood count (CBC) and continue periodic monitoring of your blood levels and chemistry while taking the drug.

Like corticosteroids and biologics, immunomodulators raise the risk of infection.


4. Biologics

Biologics act against a protein that’s part of your immune system response. Tumor necrosis factor (TNF) inhibitors are a type of biologic drug.

Another type of biologic used to treat UC is anti-interleukin 23 monoclonal antibodies (IL-23). These drugs work by blocking the immune system protein IL-23, which causes inflammation and are reserved for moderate to severe cases of UC that don’t respond well to other treatments, but are frequently used.

Biologics include the following drugs:

  • infliximab (Remicade)
  • adalimumab (Humira)
  • golimumab (Simponi)
  • vedolizumab (Entyvio)
  • ustekinumab (Stelara)
  • risankizumab-rzaa (Skyrizi)
  • mirikizumab (Omvoh)
Like certain other drugs for ulcerative colitis, biologics can increase your risk of infection. But if one of these drugs is controlling your ulcerative colitis symptoms without bothersome side effects, the benefits of continuing the drug often outweigh its risks.

5. Small Molecules

Small molecules are oral medications that also work on the immune system, but act differently from biologics. They are called small molecule drugs because rather than being proteins, like biologics, their molecular structure is similar in size to regular medications, hence their ability to be taken and absorbed orally.

Janus kinase (JAK) inhibitors like tofacitinib (Xeljanz) and upadacitinib (Rinvoq) suppress the immune system by blocking the JAK enzyme, thereby preventing it from activating specific cells that cause inflammation.

These drugs are used to treat moderate to severe ulcerative colitis.

There is an increased risk of serious heart-related events such as heart attack and stroke, cancer, blood clots, and death with tofacitinib (Xeljanz).

Ozanimod (Zeposia) is an oral small molecule medication taken once daily for adults with moderately to severely active ulcerative colitis. It’s the first in a class of drugs known as sphingosine 1-phosphate receptor modulators.

The exact way Zeposia works is unknown, but the drug is thought to act on lymphocytes, which are immune cells responsible for causing inflammation in the intestines. The drug binds to receptors on the surface of the cells, helping prevent them from moving into the colon and causing damaging inflammation.

Etrasimod (Velsipity) is an oral selective sphingosine 1-phosphate (S1P) receptor modulator used to treat moderate to severe UC. It works by reducing lymphocyte migration to sites of inflammation, thereby decreasing intestinal inflammation and promoting remission. As part of a comprehensive treatment plan, etrasimod can help manage UC symptoms and maintain long-term disease control.

Other Medication

Your doctor may prescribe or recommend these other drugs and supplements for ulcerative colitis.

Antidiarrheal Medicines While these drugs can help control diarrhea, they can also slow down your digestive function and increase your risk of toxic colitis, a severe complication. Because of these risks, antidiarrheal drugs should be used only under strict medical supervision.

Pain Relievers Your doctor may recommend acetaminophen (Tylenol) for mild pain. Avoid ibuprofen (Advil or Motrin), naproxen (Aleve), and diclofenac (Voltaren), which can cause digestive upset and worsen ulcerative colitis symptoms.

Iron Supplements These supplements may be needed if you have chronic intestinal bleeding that results in a deficiency.


The Takeaway

Ulcerative colitis is primarily managed with medication, which aims to reduce the severity and frequency of symptoms. The main classes of drugs used include aminosalicylates, corticosteroids, immunomodulators, biologics, and small molecules, with additional medications like pain relievers and iron supplements to support overall treatment. Each drug class offers unique benefits and risks, and the choice of medication depends on disease severity and each individual’s health.

Additional reporting by Ashley Welch.

Meet Our Experts
See Our Editorial PolicyMeet Our Health Expert Network
ira-daniel-breite-bio

Ira Daniel Breite, MD

Medical Reviewer
Castle Connolly Top Doctor

Ira Daniel Breite, MD, is a board-certified internist and gastroenterologist. He is an associate professor at the Icahn School of Medicine at Mount Sinai, where he also sees patients and helps run an ambulatory surgery center.

Dr. Breite divides his time between technical procedures, reading about new topics, and helping patients with some of their most intimate problems. He finds the deepest fulfillment in the long-term relationships he develops and is thrilled when a patient with irritable bowel syndrome or inflammatory bowel disease improves on the regimen he worked with them to create.

Breite went to Albert Einstein College of Medicine for medical school, followed by a residency at NYU and Bellevue Hospital and a gastroenterology fellowship at Memorial Sloan Kettering Cancer Center. Working in city hospitals helped him become resourceful and taught him how to interact with people from different backgrounds.

See full bio

Ingrid Strauch

Author

Ingrid Strauch joined the Everyday Health editorial team in May 2015 and oversees the coverage of multiple sclerosis, migraine, macular degeneration, diabetic retinopathy, other neurological and ophthalmological diseases, and inflammatory arthritis. She is inspired by Everyday Health’s commitment to telling not just the facts about medical conditions, but also the personal stories of people living with them. She was previously the editor of Diabetes Self-Management and Arthritis Self-Management magazines.

Strauch has a bachelor’s degree in English composition and French from Beloit College in Wisconsin. In her free time, she is a literal trailblazer for Harriman State Park and leads small group hikes in the New York area.

See full bio
See Our Editorial PolicyMeet Our Health Expert Network
EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Crohn’s & Colitis Foundation. What Is Ulcerative Colitis?
  2. Cheifetz AS et al. Patient Education: Sulfasalazine and the 5-Aminosalicylates (Beyond the Basics). UpToDate. May 2024.
  3. Ulcerative Colitis. Mayo Clinic. September 16, 2022.
  4. Karagozian R et al. The Role of Mesalamine in the Treatment of Ulcerative Colitis. Therapeutics and Clinical Risk Management. October 2007.
  5. Abdalla MI et al. Budesonide for the Treatment of Ulcerative Colitis. Expert Opinion on Pharmacotherapy. June 16, 2016.
  6. What Is Ulcerative Colitis? Crohn’s & Colitis Foundation.
  7. Prednisone and Other Corticosteroids. Mayo Clinic. December 9, 2022.
  8. FDA Requires Warnings About Increased Risk of Serious Heart-Related Events, Cancer, Blood Clots, and Death for JAK Inhibitors That Treat Certain Chronic Inflammatory Conditions. U.S. Food and Drug Administration. December 2021.